HopeStage
Back to all studies
TerminatedNCT01368458

Conversion to Antipsychotic Monotherapy

Interventional studyAges 18–75Schizophrenia
The study in practice

Understand this study

Who could participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 75 years. Other eligibility criteria apply.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateDecember 2007
Recruitment status
Terminated
Enrollment listed in the registry
24
Sponsor
Nathan Kline Institute for Psychiatric Research
Sponsor type
Research institute
Study type
Other
Intervention type
Other
Locations
Not clearly listed
Age range
From 18 Years to 75 Years
Official registry ID
NCT01368458
Official title
Show the full official title

A Randomized, Rater-Blind, Controlled, Clinical Trial of Conversion to Antipsychotic Monotherapy vs. Continued Polypharmacy for Patients With Schizophrenia or Schizoaffective Disorder

Recruitment & locations

Terminated

Locations not listed

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Nathan Kline Institute for Psychiatric Research, a research institute.

Who can participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 75 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies